Company intelligence / Profile preview

Longmore 60 Biotech

Adelanto, California, United Stateslongmore60.com ↗

Ownership: Private
Development stage: Other

Overview

Longmore 60 Biotech specializes in the proprietary development of biologics and biosimilars as well as providing full-service consulting across the drug development lifecycle. The company offers expertise from cloning through regulatory filing, including project planning, candidate selection, process scale-up, analytical methods, GMP manufacturing support, regulatory affairs for early phases through launch preparation. No public clinical results or proprietary pipeline programs are currently disclosed.

Modalities: BiologicBiosimilar
Industry: Drug Discovery Services

Partnerships

Works with a large network of international subject matter experts for virtual or hands-on support in drug development strategies and execution; no named major pharma/biotech partners publicly listed.

Beyond the preview

Go deeper on Longmore 60 Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Longmore 60 Biotech.

Explore the full profile